β-Blockers Myocardial Infarction: Reevaluating ...

By HEOR Staff Writer

January 14, 2026

β-blockers after myocardial infarction in patients with preserved ejection fraction (LVEF ≥50%) do not significantly improve key outcomes like mortality or recurrent events. This addresses a common query: How effective are β-blockers in post-heart...
Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays
Driving Economic Transformation through Brain Health Investment in Africa
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
Childhood Immunization Reforms: Aligning U.S. Schedules with Global Standards
Novartis Drug Pricing Agreement
mRNA Vaccine Advancements: Transforming Infectious Disease Prevention and Equity
Positive ARTISTRY-2 Trial Results for BIC LEN HIV Regimen
Accelerating Tec-Dara Multiple Myeloma Therapy Review: A Game Changer for Pat...
CHMP Meeting Highlights: December 2025 Advances in New Medicines Approvals
AKEEGA BRCA2 Approval: Landmark FDA Decision for Precision Therapy in Aggress...
Translational Medicine Portugal: Driving Collaborative Innovations in Healthcare
Arexvy RSV Vaccine Expansion: Broader Access and Impact on Adult Health Outcomes